Log in
NASDAQ:MYGN

Myriad Genetics Stock Forecast, Price & News

$12.43
-0.64 (-4.90 %)
(As of 10/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$12.22
Now: $12.43
$13.21
50-Day Range
$12.05
MA: $13.19
$14.67
52-Week Range
$9.24
Now: $12.43
$35.29
Volume604,562 shs
Average Volume997,565 shs
Market Capitalization$934.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.43
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Read More
Myriad Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.8Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.26 out of 5 stars

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MYGN
CUSIP62855J10
Phone801-584-3600
Employees2,700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$638.60 million
Cash Flow$0.59 per share
Book Value$12.32 per share

Profitability

Net Income$-199,500,000.00

Miscellaneous

Market Cap$934.82 million
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$12.43
-0.64 (-4.90 %)
(As of 10/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MYGN News and Ratings via Email

Sign-up to receive the latest news and ratings for MYGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Myriad Genetics (NASDAQ:MYGN) Frequently Asked Questions

How has Myriad Genetics' stock been impacted by COVID-19?

Myriad Genetics' stock was trading at $14.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MYGN stock has decreased by 11.4% and is now trading at $12.43.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Myriad Genetics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 3 sell ratings and 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Myriad Genetics
.

When is Myriad Genetics' next earnings date?

Myriad Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Myriad Genetics
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) announced its quarterly earnings results on Thursday, August, 13th. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.16. The business had revenue of $93.20 million for the quarter, compared to analysts' expectations of $95.44 million. Myriad Genetics had a negative net margin of 31.24% and a negative return on equity of 2.69%. During the same quarter last year, the company posted $0.41 EPS.
View Myriad Genetics' earnings history
.

What price target have analysts set for MYGN?

6 brokers have issued 12-month price targets for Myriad Genetics' shares. Their forecasts range from $10.00 to $36.00. On average, they anticipate Myriad Genetics' share price to reach $19.29 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Myriad Genetics
.

Who are some of Myriad Genetics' key competitors?

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Who are Myriad Genetics' key executives?

Myriad Genetics' management team includes the following people:
  • Mr. R. Bryan Riggsbee, Exec. VP, CFO & Treasurer (Age 49, Pay $746.48k)
  • Mr. Alexander Ford, Chief Operating Officer (Age 53, Pay $839.2k)
  • Dr. Jerry S. Lanchbury, Chief Scientific Officer (Age 61, Pay $771.75k)
  • Mr. Paul J. Diaz, CEO, Pres & Director (Age 58)
  • Mr. Scott Gleason, Sr. VP of Investor Relations

What is Myriad Genetics' stock symbol?

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.62%), Envestnet Asset Management Inc. (0.11%), Louisiana State Employees Retirement System (0.05%), DekaBank Deutsche Girozentrale (0.03%), BNP Paribas Arbitrage SA (0.02%) and KBC Group NV (0.02%). Company insiders that own Myriad Genetics stock include Alexander Ford, Bernard Tobin, Gary A King, John T Henderson, Nicole Lambert, Ralph L Mcdade, Richard Bryan Riggsbee and Walter Phd Gilbert.
View institutional ownership trends for Myriad Genetics
.

Which institutional investors are selling Myriad Genetics stock?

MYGN stock was sold by a variety of institutional investors in the last quarter, including Pinnacle Associates Ltd., KBC Group NV, and Nisa Investment Advisors LLC. Company insiders that have sold Myriad Genetics company stock in the last year include Alexander Ford, and Nicole Lambert.
View insider buying and selling activity for Myriad Genetics
.

Which institutional investors are buying Myriad Genetics stock?

MYGN stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., DekaBank Deutsche Girozentrale, Louisiana State Employees Retirement System, Integrated Investment Consultants LLC, Pacer Advisors Inc., BNP Paribas Arbitrage SA, and Envestnet Asset Management Inc.. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, and Walter Phd Gilbert.
View insider buying and selling activity for Myriad Genetics
.

How do I buy shares of Myriad Genetics?

Shares of MYGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Myriad Genetics' stock price today?

One share of MYGN stock can currently be purchased for approximately $12.43.

How big of a company is Myriad Genetics?

Myriad Genetics has a market capitalization of $934.82 million and generates $638.60 million in revenue each year. The company earns $-199,500,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Myriad Genetics employs 2,700 workers across the globe.

What is Myriad Genetics' official website?

The official website for Myriad Genetics is www.myriad.com.

How can I contact Myriad Genetics?

Myriad Genetics' mailing address is 320 WAKARA WAY, SALT LAKE CITY UT, 84108. The company can be reached via phone at 801-584-3600 or via email at [email protected]

This page was last updated on 10/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.